ProQR's AX-0810 Shows Positive Phase 1 Data, Validating RNA Editing Platform
PRQR sits 51% above its 52-week low of $1.33.
Summary
ProQR announced positive Phase 1 target engagement data for AX-0810, marking the first clinical validation of its Axiomer RNA editing platform. The study demonstrated dose-dependent increases in total bile acids up to 8-fold, exceeding the predefined 2-fold threshold, along with a favorable safety profile. This is a critical de-risking event for the company's core technology and pipeline, providing a significant positive development after a recent Q1 earnings miss and a shareholder dispute over capital increases. Full data from the Phase 1 study is expected to be presented later.
At the time of this announcement, PRQR was trading at $2.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.7M. The 52-week trading range was $1.33 to $3.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.